The European experience with docetaxel in the treatment of early-stage breast cancer

Clinical Breast Cancer

Volumn 3, Issue SUPPL. 2, 2002, Pages

  Leo, Angelo D ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

5 fluorouracil; Anthrac ylines; Cyclop hosphamide; Doxoru bicin; p53 gene; Polychem otherapy; Sequential therapy; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA TUBULIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; METHOTREXATE; MICROTUBULE ASSOCIATED PROTEIN; MOLECULAR MARKER; ONCOPROTEIN; PACLITAXEL; PROTEIN P53; TAXANE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; EARLY CANCER; EUROPE; GENE MUTATION; HUMAN; MEDICAL RESEARCH; MOLECULAR BIOLOGY; PREDICTION; PROSPECTIVE STUDY; PROTEIN EXPRESSION;

EID: 0036815555     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/cbc.2002.s.013     Document Type: Article

References (17)

1. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. The 304 Study Group. J Clin Oncol 1999; 17:1413-1424.
2. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17:2341-2354.
3. Nabholtz J, Falkson G, Campos D, et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC. Proc Am Soc Clin Oncol 1999; 18:127a (Abstract #485).
4. Nabholtz JM, Paterson A, Dirix L, et al. A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients (Pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2001; 20:22a (Abstract #83).
5. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2:811-814.
6. Fan S, Cherney B, Reinhold W, et al. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 1998; 4:1047-1054.
7. Lanni JS, Lowe SW, Licitra EJ, et al. p53 independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A 1997; 94:9679-9683.
8. Ishioka C, Frebourg T, Yan YX, et al. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 1993; 5:124-129.
9. Sjogren S, Inganas M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88:173-182.
10. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-10874.
11. Konecny G, Thomssen C, Pegram M, et al. HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20:23a (Abstract #88).
12. Henderson IC, Berry D, Demetri G, et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 1998; 17:101a (Abstract #390).
13. Dumontet C and Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17:1061-1070.
14. Veitia R, Bissery MC, Martinez C, et al. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice. Br J Cancer 1998; 78:871-877.
15. Bernard C, Fellous A, Di Leo A, et al. Evaluation of microtubule associated parameters as predictive markers for advanced breast cancer patients treated with docetaxel. Eur J Cancer 2001; 37 (suppl 6):S182 (Abstract #666).
16. Jarvinen TA, Tanner M, Barlund M, et al. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999; 26:142-150.
17. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156:839-847.